Top 14+ Cc-92480-mm-003 hay nhất
-
1.A Study To Determine The Recommended Dose And ... - Clinical Trials
18 Jun 2019 · Brief Summary: The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
Xem chi tiết » -
2.A Safety, PK And Efficacy Study Of CC-92480 Monotherapy And In ...
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) ...
Xem chi tiết » -
3.Phase I Trial Supports CC-92480 For Heavily Pretreated Myeloma
1 Sept 2020 · Results from a first-in-human trial of CC-92480 in patients with relapsed or refractory multiple myeloma show a manageable safety profile ...
Xem chi tiết » -
4.CELMoD CC-92480/Dexamethasone Combo Shows Early Activity In ...
6 Dec 2020 · CC-92480, a novel oral cereblon E3 ligase modulator agent, plus dexamethasone demonstrated immunomodulatory activity across all dose levels ... Missing: 003 | Must include: 003
Xem chi tiết » -
5.Mezigdomide - Bristol-Myers Squibb - AdisInsight - Springer
The efficiency of POM or CC 92480 induced PBMC mediated killing in a dose ... Preclinical studies with mezigdomide in multiple myeloma (MM) showed that ...
Xem chi tiết » -
6.Novel Non-Immunologic Agents For Relapsed And Refractory ... - NCBI
18 Oct 2021 · CC-92480 was tested in a multicenter phase I trial ... and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial. The New Generations of... · Targeting New Pathways in... · New Emerging Agents...
Xem chi tiết » -
7.Promising Therapeutic Approaches For Relapsed/refractory Multiple ...
Objective: Treatment strategies for relapsed/refractory MM are particularly complex. In ... escalation trial CC-92480-MM-001 (NCT03374085) is.
Xem chi tiết » -
8.The Changing Landscape Of Relapsed And/or Refractory Multiple ...
9 Jan 2022 · The combination of CC-92480 plus dexamethasone was tested in a phase 1 ... relapsed and refractory multiple myeloma (MM-003): a randomised, ...
Xem chi tiết » -
9.Aiding Early Clinical Drug Development By Elucidation Of The ...
19 May 2022 · The CC-4047-MM-003 (NCT01311687) study was a phase III, mul- ... CC-92480 [32], which have shown promising clinical outcomes, are.
Xem chi tiết » -
10.Treatment Options For Patients With Heavily Pretreated Relapsed ...
18 Jan 2022 · Patients with relapsed MM that is refractory to an ... and bortezomib was shown in the pivotal phase III MM-003 study, ... CC-92480.
Xem chi tiết » -
11.[PDF] Developing Next Generation Immunomodulatory Drugs And Their ...
20 Jul 2021 · Multiple Myeloma (MM) is an incurable malignancy with current treatment ... CC-92480 have included 85–90% MM patients who are.
Xem chi tiết » -
12.CC-92480 Shows Encouraging Efficacy In First-in-Human Study For ...
30 May 2020 · An ongoing study of CC-92480 in combination with dexamethasone demonstrated favorable activity and safety data in patients with heavily ... Missing: 003 | Must include: 003
Xem chi tiết » -
13.Bristol Myers Squibb To Highlight More Than 80 Abstracts At ASH ...
First clinical results for anti-SIRPα antibody CC-95251 and CELMoD ... of preliminary results from the Phase 1/2 MM-002 study of CELMoD® CC-92480 in ...
Xem chi tiết » -
14.Multiple Myeloma Clinical Trials In Georgia
Cancer Type. Multiple Myeloma. NCT ID. NCT03374085. Protocol IDs. CC-92480-MM-001. NCI-2018-00132. U1111-1205-3650 2017-001236-19. Treatment Sites (1).
Xem chi tiết »